MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
May 30, 2023 05:00 ET
|
AKAMPION
FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)DMD is a designated orphan disease in both Europe and the...
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
May 30, 2023 04:00 ET
|
AKAMPION
Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late...
Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
May 24, 2023 04:00 ET
|
AKAMPION
- Addressing high unmet medical need in locally advanced soft tissue sarcoma- Targeted tumor treatment independent of specific molecular targets or tumor subtypes Munich, Germany – May 24,...
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
May 24, 2023 04:00 ET
|
AKAMPION
- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
May 12, 2023 04:00 ET
|
AKAMPION
ROTTERDAM, May 12, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the...
Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
May 09, 2023 03:30 ET
|
AKAMPION
Data presented at RACS 91st Annual Scientific Congress 2023Initial findings demonstrate that BellaSeno’s resorbable implants are safe, well tolerated and lead to natural tissue growth Leipzig,...
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
May 08, 2023 03:30 ET
|
AKAMPION
- OMN6 demonstrates safety and tolerability at clinically significant dose levels JERUSALEM, Israel, May 8th, 2023 -- Omnix Medical, a biopharmaceutical company developing next-generation...
ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
April 25, 2023 04:00 ET
|
AKAMPION
- Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 –...
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
April 12, 2023 08:00 ET
|
AKAMPION
Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material...
EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases
April 03, 2023 04:00 ET
|
AKAMPION
Presentation at the World Vaccine Congress 2023EBV-infections associated with many cancers and multiple sclerosis Munich, Germany, April 3, 2023 – EBViously, a start-up developing novel vaccines...